Clinical Trials Browser

Phase 1/2 × Multiple Myeloma × Injections, Subcutaneous × Clear all

NCT00821249 2020-10-19

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma